Concepedia

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Stefan Schreiber, Paul Rutgeerts, Richard N. Fedorak, Munaa Khaliq–Kareemi, Michael A. Kamm, Michel Boivin, Çharles N. Bernstein, Michael Staun, Ole Østergaard Thomsen, Alison Innes

Gastroenterology · 2005 · 581 citations · 33 references

DOI

Concepts

References

33

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations

, , +12

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Joseph Keane, Sharon K. Gershon, Robert P. Wise et al. · New England Journal of Medicine · 2001 · 3.7K citations · Full text

, , +16

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

William R. Best, Jack M. Becktel, John W. Singleton et al. · PubMed · 1976 · 3.2K citations

, , +15

Development of a Crohn's Disease Activity Index

William R. Best, Jack M. Becktel, John W. Singleton et al. · Gastroenterology · 1976 · 3.2K citations

, , +12

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.2K citations · Full text

, , +12